

1 **Title: A non-inferiority randomised controlled trial to assess the risk of onward infection transmission from**
2 **contacts of confirmed COVID-19 cases who use daily lateral flow tests to enable exemption from isolation**
3 **compared to standard self-isolation**

4
5 Author Names and preferred degree: Nicola K Love PhD¹, Derren R Ready PhD^{1,2}, Charlie Turner PhD¹, Neville
6 Q Verlander MSc¹, Clare E French PhD², Alex F Martin MSc⁵, Tina B Sorensen PhD¹, Soeren Metelmann PhD
7 ¹, Sarah Denford PhD^{2,3,5}, G James Rubin PhD⁵, Lucy Yardley PhD^{2,4,5}, Richard Amlot PhD^{1,2,5}, Susan Hopkins
8 FRCP¹, Isabel Oliver FFPH^{1,2}

9
10 Affiliations and full address

- 11 1. UK Health Security Agency, England, UK
- 12 2. Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol, Bristol,
13 UK
- 14 3. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 15 4. Health Protection Research Unit in Emergency Preparedness and Response at King's College London,
16 London, UK.
- 17 5. School of Psychological Science, University of Bristol, Bristol, UK
- 18 6. School of Psychological Science, University of Southampton, Southampton, UK

19
20 Corresponding

21 Professor Isabel Oliver, UK Health Security Agency, Wellington House, 133-155 Waterloo Road, London
22 SE1 8UG
23 isabel.oliver@phe.gov.uk

24
25 Keywords

26 COVID-19; SARS-CoV-2; Lateral flow testing; Contacts; testing, DCT

27 **Summary [300]**

28 **Background:** In the UK, during the study period all COVID-19 contacts were required to self-isolate for 10 days,
29 which had adverse impacts. Avoiding the need to self-isolate for those who remain uninfected would be beneficial
30 to society. We investigated whether using daily lateral flow devices (LFDs) to test for COVID-19 with removal
31 of self-isolation for 24 hours if negative was a safe alternative to self-isolation by determining tertiary attack rates
32 in study groups.

33 **Methods:** We conducted a non-inferiority randomised controlled trial (Research Registry ID:6809) in a adult
34 contacts identified during COVID-19 contact tracing. Consented participants were randomised to self-isolation
35 (SI; single PCR, 10 days isolation) or daily contact-testing (DCT; 7 LFDs, 2 PCRs, no isolation if negative on
36 LFD); participants from a household were assigned to the same arm. Participants were prospectively followed-up
37 with the impact of each intervention on onward transmission determined from routinely collected contact tracing
38 data for COVID-19 participants, and tertiary cases arising from their contacts. Attack rates were derived from
39 cluster-robust standard error Bernoulli regression models. Questionnaires were sent at recruitment and at the end
40 of testing/self-isolation to assess behaviours.

41 **Findings:** 49,623 individuals consented to participate with final arm allocations of 26,123 DCT (52.6%) and
42 23,500 SI participants (47.4%). Overall, 4,561 participants tested positive by PCR (secondary cases); 2,359
43 (10.0%) in the SI arm and 2,202 (8.4%) in the DCT arm. Tertiary attack rates (among secondary contacts) were
44 7.49% in SI arm and 6.40% in DCT arm (difference of -1.09 % (95% Confidence Interval -2.16% to -0.03%)),
45 124,010 valid LFD results were reported from 20,795 (79.6%) DCT participants with 1,132 (5.4%) reporting a
46 positive result. Using DCT released each participant from self-isolation for an average of 5.4 days, (total time
47 released:121,115 days).

48 **Interpretation:** DCT with 24-hour exemption from self-isolation for essential activities appears to be non-inferior
49 to self-isolation.

50 **Introduction**

51

52 In England, the NHS Test and Trace (NHSTT) programme provides access to testing and contact tracing for close
53 contacts of confirmed COVID-19 cases (1). At the time of this study (April-July 2021) all contacts, vaccinated
54 and unvaccinated were required to isolate for 10 days from the date of exposure to the primary case. In August
55 2021, vaccinated contacts and those under 18 years and 6 months were no longer required to isolate but
56 unvaccinated adult contacts were required by legislation self-isolate for 10 days from the date of their last exposure
57 to the case. All COVID-19 contacts have been offered a single PCR test, irrespective of symptoms since March
58 2021 (2); however only half of identified contacts performed this test. Most contacts of COVID-19 cases modify
59 their behaviours and contact with other people. However, full adherence to self-isolation guidance in England
60 remains between 50-80% (3-5), reducing the effectiveness of isolation on viral transmission. Strategies for
61 improving self-isolation compliance have been developed, including provision of financial or other incentives and
62 penalties (6). However, such strategies do not consider the wider economic, social and well-being impacts of self-
63 isolation (7).

64

65 Strategies that target self-isolation more effectively to contacts who become infected, while allowing those
66 without infection to continue with essential activities, would help society return to greater normality while
67 continuing to reduce onward transmission. Improving case ascertainment through the identification of
68 asymptomatic, pauci-symptomatic and pre-symptomatic cases could help target isolation most effectively and,
69 potentially, improve adherence to self-isolation guidance (8-10). Asymptomatic, rapid antigenic testing using
70 lateral flow devices (LFDs) for COVID-19 is widely available in the UK (11-12), with low cost, rapid turn-around
71 times, and delivery outside of a routine laboratory environment. Such tests could be suitable to support a structured
72 programme of testing contacts of cases (8-10).

73

74 Two previous feasibility and acceptability studies demonstrated the potential benefits of a structured programme
75 of daily testing of contacts using either a single PCR (13) or a 'test to enable' approach using daily LFDs plus one
76 PCR as part of the contact tracing process in England (14-17). However, these studies were not designed to assess
77 the risk of onward transmission. The use of daily contact testing using LFDs as an alternative to self-isolation was
78 explored in a school-based study, which reported that the use of daily LFDs was non-inferior to self-isolation for
79 control of COVID-19 transmission (18). Here we report the results of a non-inferiority randomised controlled trial
80 of a dult, close contacts of COVID-19 cases to test whether using daily LFDs with 24-hour exemption from self-
81 isolation following each negative LFD result, in combination with 2 PCR tests, was a safe alternative to self-
82 isolation combined with a single PCR test.

83 **Methods**

84 **Study design and recruitment**

85 The study design was a two-arm, non-inferiority non-blinded randomised controlled trial. Adults (≥ 18 years),
86 vaccinated and unvaccinated, identified as contacts of confirmed COVID-19 cases, living in England, were
87 offered participation in the study (Supplementary Figure 1 and Supplementary methods). Participants were not
88 eligible to participate if they were; symptomatic at recruitment; under travel associated quarantine; participating
89 in a workplace DCT programme; resident in a prison or social care institution; a contact of a case with a variant
90 of concern (VOC; between 29-April–7-June-2021 only; removed after this date to ensure generalisability for
91 Delta); or did not provide an email address. Individuals were recruited through the routine contact tracing process
92 and selected sequentially. Information on eligibility criteria were self-reported. Self-reported age, postcode, VOC,
93 and travel criteria were confirmed using data collected by NHSTT during contact tracing. Recruitment was
94 performed daily from 29-April to 28-July-2021 with eligible contacts invited to take part via recruitment phone
95 calls or via SMS/emails containing a link to self-register online. There was no limit on daily recruitment; however,
96 due to intermittent limitations in the number of kits available, enrolment was restricted between 26–29-June, 03-
97 12-July and 19-26-July. A sub-set of participants were interviewed after completing testing/self-isolation as part
98 of a nested qualitative component to the study, which is reported elsewhere (19).
99

100 Ethical approval was granted by Public Health England Research Ethics and Governance Group (ref:NR0235)
101 and the protocol was registered with the Research Registry (ID:6809). Informed consent was obtained during
102 recruitment.
103

104 **Sample size calculation**

105 Allowing for attrition and testing compliance, 40,000 participants were required to generate 3,170 secondary
106 contacts based on a non-inferiority sample size calculation using a significance level of 0.05, power of 80%, ratio
107 of group sizes 1:1, and design effect of 1.2, derived from a difference of proportions of 6.3% in DCT vs. 8.2% in
108 general population comparator as reported in (14). At the study mid-point, the sample size was inflated to 50,000
109 to account for a lower than expected detection of COVID-19 in contacts, suspected to be related to vaccination.
110

111 **Randomisation**

112 Participants were randomly assigned to either the DCT arm (daily contact testing with 7 self-administered LFDs
113 with release for 24 hours based on a negative LFD result) or the Standard Isolation (SI) arm (a single self-taken
114 PCR swab and self-isolation for 10 days), with randomisation occurring at the point of consent based on a system-
115 generated timestamp for a participant. Contacts from the same household were assigned to the arm of the first
116 member of the household recruited, irrespective of the outcome of randomisation.
117

118 **Procedures and data collection**

119 Demographic data were collected at recruitment using a secure electronic questionnaire (SnapSurvey, Snap 11
120 Professional) and downloaded twice daily to produce lists for test kit postage and messaging. Kits were posted
121 via NHSTT home delivery channels. Within 24 hours of recruitment, participants with a valid mobile number
122 and/or email address were informed of their assigned study arm and sent a link to a short, voluntary, anonymous
123 baseline questionnaire. On day 7, a link was sent with a completion of study questionnaire. Reminder messages
124 were sent after 48 hours.
125

126 Participants in both arms were asked to take a self-sample for PCR on day of kit arrival and return it by post. DCT
127 participants were asked to perform their first LFD on day of kit arrival and then on each of the following 6 days,
128 reporting results daily to a secure study portal (SnapSurvey). Reported results were submitted to the national
129 results database in compliance with infectious disease notification regulations. On reporting their first negative
130 LFD, DCT-participants were assigned a flag in the NHSTT contact tracing system to prevent isolation checks and
131 access to self-isolation support payments. A second PCR swab was requested for DCT participants on receipt of
132 an LFD-positive result or on the day of their last LFD (if all previous LFDs were negative). All participants were
133 legally required to self-isolate for 10 days if PCR-positive. No formal restrictions were placed on study

134 participants in the DCT arm during periods free from self-isolation; however, participants were advised to
135 minimise contact and undertake only essential activities.

136

137 **Outcomes**

138 The primary outcome was to determine if DCT was inferior to SI by ascertaining the proportion of secondary
139 contacts (close contacts of COVID-19 positive study participants), who became COVID-19 cases (tertiary cases)
140 in each arm.

141

142 Secondary outcomes of the study were to determine the feasibility and acceptability of each strategy by measuring
143 uptake and compliance with testing, ascertaining the proportion of positive results, describing the concordance of
144 PCR and LFD results, describing participant behaviours during the study period, establishing the number of
145 working days enabled for DCT-participants and understanding factors influencing the use of tests, understanding
146 of test results, and how tests inform behavioural decisions (reported in (19)).

147

148 **Data analysis**

149 Data submitted to the study LFD portal and recruitment portal were analysed as of 14-August-2021, with PCR
150 data analysed as of 8-September-2021. Data were analysed in Stata version 15 and R Studio version 4.0.0.
151 Recruitment data were enriched using routinely collected NHSTT contact tracing data and deterministically linked
152 to PCR results from national laboratory surveillance, study LFD results, the national LFD result portal and to
153 immunisation data from the National Immunisation Management System (NIMS) using a combination of
154 identifiers. PCR results from all participants were restricted to tests with a specimen date in the 90 days prior to
155 recruitment (to adjust for extended PCR positivity) to 14 days after recruitment. Fully and one dose vaccinated
156 individuals were defined as those vaccinated more than 14 days prior to recruitment. Where NIMS vaccination
157 status was unknown, self-reported vaccination status was used.

158

159 Participants were excluded if they met the exclusion criteria, if no address was provided, or the same participant
160 was registered multiple times (with an alternative contact tracing ID) within 3 days. Descriptive analyses
161 determined associations by chi-squared and rank sum tests, with a p-value of <0.001 used to assign significance
162 due to the large study population. The second behavioural questionnaire was analysed as three groups (SI, DCT-
163 tested positive, DCT-no positive test). For both behavioural questionnaires, proportions were calculated among
164 participants, who provided a least one response to a question and were compared using chi-squared tests.

165

166 Attack rates were derived from participants (primary contacts), who tested positive for SARS-CoV-2 by PCR in
167 the 2 days before and 14 days after recruitment (secondary cases). SI participants who reported LFDs to the study
168 portal were excluded (n=43). Participants were deterministically linked to case episodes in CTAS and their named
169 close contacts identified. Potential transmission events were defined as contact records matched to a subsequent
170 case record with symptom onset (test date if asymptomatic) between 2-14 days (inclusive) after the exposure date.
171 Where the contact was in the household, the date of symptom onset (test date if asymptomatic) of the exposurer was
172 taken as the exposure date. Where multiple case-contact exposures could have resulted in transmission, rules-
173 based prioritisation (preferring household exposures, and most recent exposures) identified a single most likely
174 potential transmission event. The attack rate was the proportion of contacts of participants (secondary contacts)
175 that were identified as potential transmission events, leading to tertiary cases. Attack rates were derived from
176 Bernoulli regression models with cluster-robust standard errors. The simplest 'unadjusted' model used arm as the
177 only covariate. The second 'unadjusted' model added household exposure and its interaction with arm, while the
178 third 'unadjusted' model instead added vaccine status (0 or 1; 2 doses) and its interaction. 'Adjusted' versions of
179 these models were obtained by adding household exposure, vaccine status and ability to work from home.
180 Interactions were tested for significance by Wald tests with significance level of 0.05. Sensitivity analyses
181 restricted to DCT-participants who submitted LFD results to the study portal (as a proxy for compliance) and the
182 first household member recruited (to account for allocation to the same arm for multiple household members) and
183 with both restrictions were performed. An independent unadjusted masked analysis was also performed.

184

185 **Results**

186 57,430 unique contacts of confirmed cases of COVID-19 consented to participation in the study (Figure 1). 60.2%
187 of participants self-enrolled digitally (n=34,580) and 39.8% enrolled via telephone calls (n=22,850).
188 54,923/57,430 (95.6%) consenting individuals were eligible for inclusion (n=1,169 had no address or contact
189 information, n=369 met exclusion criteria, n=969 were duplicate participants). 27,741 participants were randomised
190 into the DCT arm (50.5%) and 27,182 into the SI arm (49.5%). 5,300 participants withdrew after randomisation
191 (2,634 (49.7%) DCT-participants and 2,666 SI-participants); common reasons for withdrawing were
192 dissatisfaction with arm allocation (n=1,453), being at the end of isolation (n=770), having a previous PCR test
193 (n=568), and already testing positive (n=453; Supplementary Table 1). Household members were grouped into
194 the same study arm after randomisation, with final arm allocations being 26,123 DCT-participants (52.6%) and
195 23,500 SI-participants (47.4%).

196

197 **Baseline characteristics**

198 There were no statistical differences in the sex, age, regional distribution or ethnicity, vaccination status or the
199 presence of a COVID-19 case in the household between the two arms (Table 1 and Supplementary Table 2). DCT-
200 participants were significantly less likely to work outside of the home (40.1% vs. 43.2%; ; p=<0.001). 41.7% of
201 DCT-participants and 36.1% of SI-participants had more than one household member in the study or registered
202 more than once during recruitment (p=<0.001).

203

204 **Transmission from participants who became cases**

205 Of the 49,623 participants (primary contacts), 2,359 (10.0%) reported at least one positive PCR result in the SI
206 arm and 2,202 (8.4%) in the DCT arm in the period between 2 days prior to recruitment and 14 days after
207 recruitment, hereafter referred to as secondary cases. 4,561 were linked to 4,615 cases in the NHSTT contact
208 tracing database (where a case had multiple records, all were included). 3,710/4,615 cases (80.4%) reported at
209 least one contact (secondary contacts); 1,948/2,385 (81.7%) PCR-positive SI-participants and 1,762/2,230
210 (79.0%) PCR-positive DCT-participants (Table 2). In total, 10,115 secondary contacts were reported; 5,206
211 contacts reported by SI-participants and 4,909 contacts reported by DCT-participants. Of these secondary
212 contacts, 704 became tertiary cases (390 from SI-participants and 314 from DCT-participants).

213

214 Overall, 2.19 secondary contacts were reported per secondary case (2.18 per case in the SI arm and 2.20 per case
215 in the DCT arm; no statistical difference), with the majority of these being household contacts (1.94 household
216 secondary contacts per case in SI arm and 1.93 in DCT arm). The number of tertiary cases per secondary case was
217 0.14 in the DCT arm and 0.16 in the SI arm. Attack rates among secondary contacts were 7.49% in the SI arm and
218 6.40% in the DCT arm. The percentage difference between the arms was -1.09% (95% Confidence Interval (CI):
219 -2.16% to -0.03%), suggesting that DCT is non-inferior to SI (Table 3).

220

221 Attack rates among secondary household contacts of secondary cases were 6.9% in the DCT arm and 8.0% in the
222 SI arm, though not significantly different (percentage difference: -1.10%; CI: -2.26% to 0.06%). Attack rates
223 amongst non-household secondary contacts did not differ between the DCT arm (2.98%) and the SI arm (3.52%)
224 (percentage difference: -0.54% (CI: -2.72% to 1.64%)).

225

226 Attack rates did not significantly differ between arms for secondary contacts who were unvaccinated or partially
227 vaccinated (6.93% in DCT arm and 7.78% in SI arm; percentage difference: -0.85% (CI: -2.34% to 0.64%)). The
228 difference was greater in magnitude, but not significant for fully vaccinated secondary contacts (5.72% in DCT
229 arm vs 7.06% in SI arm; percentage difference: -1.33% (95% CI -2.84% to 0.17%)).

230

231 Results from models testing arm and household exposure interaction and arm and vaccination status interaction
232 were not significant (Table 3).

233

234 **LFD testing uptake and compliance**

235 Between 30-April and 9-August-2021, 124,010 unique LFD test results were reported to the study portal from
236 20,795 DCT-participants (79.6%); 5,328 DCT-participants did not report LFD results to the study portal; of

237 whom 1,300 reported at least one result to the national, non-study portal (Supplementary Table 3). These 5,328
238 participants were excluded from subsequent analyses because it was unknown if these individuals intended to
239 follow the 24-hour release approach given the widespread use of LFD testing in England. Demographic
240 characteristics differed significantly between people who did and did not report an LFD result to the portal.
241 Individuals in lower index of multiple deprivation (IMD) deciles, minority ethnicity background and those unable
242 to work from home were less likely to report a result (Supplementary Table 4). 19,663/20,795 DCT-participants
243 (94.6%) reported only negative and/or void LFD results and 1,132/20,795 DCT-participants (5.4%) reported at
244 least one positive LFD result.

245

246 A sensitivity analysis removed DCT-participants who had not submitted an LFD result to the study portal
247 (Supplementary Table 5 and 6), again indicating that DCT was non-inferior to SI (attack rates: 7.49% in the SI
248 arm and 6.00% in the DCT arm). A separate sensitivity analysis which restricted to the first person recruited in
249 the household (Supplementary Table 7 and 8) also indicated that DCT was non-inferior to SI (attack rates: 7.15%
250 in the SI arm and 6.45% in the DCT arm). Results of a further sensitivity analysis that combined both restrictions,
251 considering only the first person recruited in the household after exclusion of those DCT-participants who had not
252 submitted a LFD result to the study portal, was also consistent with results of the main analysis (Supplementary
253 Table 9 and 10).

254

255 **Days of self-isolation exemption enabled by DCT**

256 For DCT participants who worked outside of the home and did not test LFD or PCR-positive during their testing
257 period (n=7,457) the number of days free from self-isolation and therefore the number of work days enabled
258 through DCT were estimated at up to 44,089 days (a average of 5.9 days per participant). Overall, the number of
259 days free from self-isolation among DCT-participants who reported LFDs, was estimated as 121,115 days
260 (a average of 5.4 days per participant).

261

262 **PCR testing uptake and compliance**

263 62,190 valid PCR results with specimen dates 2 days before recruitment to 14 days post recruitment (to cover a
264 full incubation period) were obtained from 34,958 participants using England's national laboratory surveillance
265 system; 17,344/23,457 (73.9%) from SI-participants and 17,614/20,795; (84.7%) from DCT-participants (Table
266 4), 316 results were void (0.5%).

267

268 The median number of PCR tests taken by participants during this time period was 2 for both arms (SI: IQR=2;
269 Range: 0-9 and DCT: IQR=1; Range 0-8), with 12,061 (68.5%) of DCT-participants submitting two or more PCR
270 swabs in the 14 days following recruitment, as directed by the study protocol. Of 17,614 DCT-participants who
271 submitted an LFD to the study portal, 1,647 had a positive PCR result (9.4%).

272

273 **Behavioural survey**

274 31,660 (63%) participants responded to the baseline questionnaire; 17,694 in the SI and 13,966 in the DCT arm;
275 69% of all respondents reported participating in the study as they wanted to avoid self-isolating if possible
276 (Supplementary Table 11).

277

278 20,004 (40%) participants responded to the end of study questionnaire (8,807 SI-participants, 754 in the DCT –
279 tested positive group and 10,443 in the DCT –no positive test; Table 5). 82% of individuals in the SI arm reported
280 much less contact with non-household contacts in the previous 7 days compared with the week prior, as did 84%
281 of individuals in the DCT – tested positive group. In the DCT-no positive test group, 57% reported much less
282 contact, with 11% of participants reporting having much or slightly more contact.

283

284 Participants were asked about any reasons for leaving home whilst self-isolating. The most common response was
285 to take a COVID-19 test (87% of those who reported a reason in both groups). The proportion of participants who
286 reported at least one other activity outside of the home whilst self-isolating was similar between the SI and DCT-
287 tested positive groups (16% and 17% respectively, p=0.80).

288

289 In the SI group most respondents (79%) were very or completely confident in the accuracy of their test results.
290 This level of confidence was reported by 64% of participants in the DCT–tested positive group and 83% in the
291 DCT-no positivetest group.

292
293

294 **Discussion**

295 As the COVID-19 pandemic continues to have a major impact on health and society, it is important to make efforts
296 to reduce transmission. While self-isolation of confirmed cases and their contacts can be effective, it is also
297 disruptive for society and causes adverse impacts for individuals, given the practical, financial, and psychological
298 challenges associated with sustained and repeated self-isolation. To address these challenges, it has been proposed
299 that innovative approaches could limit self-isolation to those who are infected, whilst allowing those without
300 infection to return to greater normality (14, 20). While previous studies showed that DCT was acceptable to
301 participants (14-16), they were not powered to assess the potential transmission risk to others.

302

303 Here we present results of the first randomised controlled trial in a general population of close contacts of COVID-
304 19 cases comparing self-isolation to DCT with 24 hours exemption from self-isolation after a negative LFD result.
305 By ascertaining the proportion of contacts of PCR-positive study participants who became tertiary cases in each
306 arm, we demonstrated that DCT was a safe alternative to SI regarding onwards transmission of SARS-CoV-2,
307 with a difference in attack rates of -1.09% amongst contacts of secondary cases, indicating non-inferiority of DCT.
308 Consistent with this finding, the number of observed tertiary cases per secondary case was 0.14 in the DCT arm
309 and 0.16 in the SI arm. Attack rates among contacts of DCT-participants, who had received two vaccine doses
310 (>14 days before recruitment) also showed non-inferiority compared to SI-participants, with an unadjusted
311 difference between DCT and SI arms (SI as baseline) of -1.33%. This suggests DCT would be of value among
312 fully vaccinated people. Although there was some imbalance in the study arms due to household clustering, a
313 sensitivity analysis restricted to the first person recruited also showed DCT was non-inferior to SI. Other
314 sensitivity analyses adjusting for non-reporting of LFD results supported the plausibility of DCT non-inferiority.

315

316 While the study did not set out to change behaviour, individuals in the DCT group who reported only negative
317 test results did not report significantly more contacts than those who were self-isolating, with the majority of
318 contacts reported by participants in both arms being household contacts. This study occurred prior to the removal
319 of all social restrictions. It is possible that DCT may perform differently in the absence of any social restrictions
320 when cases are likely to have a higher number of close contacts beyond the household.

321

322 Compliance with testing was high with 80% of DCT-participants submitting at least one LFD result, higher than
323 the 70.2% observed in the pilot study (14). Furthermore, 73.9% of SI-participants and 84.7% of DCT-
324 participants had at least one PCR test during the study, higher than the 40% return rate reported in a previous
325 study (13). Currently in England, it is recommended that all close COVID-19 contacts take a PCR test, with
326 compliance in the general population lower than in our study (48.2% of household contacts and 36.3% of non-
327 household contacts in the general population 0-10 days after exposure; in an email from P. Patrzylas
328 (piotr.patrzylas@phe.gov.uk) in November 2021). The usage of LFDs was common for participants in the SI
329 arm. Many non-reporting individuals from the DCT arm and individuals in the SI arm submitted at least one
330 LFD to the non-study result portal, which may suggest LFDs provided reassurance to SI-participants, as well as
331 DCT-participants. This was adjusted for in a sensitivity analysis, with similar findings.

332

333 DCT-participants living in more socioeconomically deprived areas and those from minority ethnic backgrounds
334 were less likely to report an LFD result, aligning with previous findings (14,16). The ineligibility of DCT-
335 participants for isolation support payments may have resulted in lower compliance among participants in lower
336 socioeconomic groups (4). Prior to introducing any DCT policy it will be important to engage with disadvantaged
337 communities to further understand and address barriers to testing and reporting.

338

339 The average number of close contacts reported was low (2.7 contacts per case), consistent with the national
340 experience (20). Around 80% of secondary cases (participants who tested positive by PCR) provided details of

341 their contacts to NHSTT, which was comparable to figures for overall compliance with the contact tracing
342 programme (20). During the study period 30-50% of contacts notified to NHSTT in England were non-household
343 contacts (20). This was substantially higher than the proportion of non-household contacts reported in the study
344 for both arms (~12%), with the number of non-household contacts per case near-equivalent between arms. This
345 lower number of non-household contacts may indicate increased caution as described in qualitative analysis (19)
346 or a ascertainment bias towards being early in isolation period. Study participants were aware of their contact status
347 prior to becoming cases and therefore may have different behaviours to the general case population, which
348 includes cases who were not previously aware of their contact status. Although additional freedom was offered to
349 DCT-participants, individuals in the DCT arm were still advised to limit contact and that they should only engage
350 in essential activities. Behavioural data suggest that DCT-participants limited their contact with others and
351 remained cautious in their behaviours despite enjoying additional freedom (19). For example, 57% of DCT-
352 participants reported having much less contact with people they did not live with in the last seven days, compared
353 to the week before, with only 11% of DCT-participants reporting having much or slightly more contact. In
354 contrast, around 80% of participants in both the SI arm and the DCT-positive test group reported much less
355 contact with non-household contacts, with compliance with self-isolation comparable to estimates from a study
356 conducted by ONS (5).

357
358 The key strengths of this RCT include its large size, the real-life setting using existing contact tracing systems and
359 validity of the transmission measure due to the use of named contacts identified by their expositors. There are,
360 however, some limitations. We relied on self-notification of close contacts, which could lead to under
361 ascertainment, particularly of non-household contacts. These limitations are also limitations of the existing contact
362 tracing system. Furthermore, it was not possible to assess the risk of transmission beyond named close contacts.
363 The attack rates should be considered minimum estimates because only contacts who access testing can
364 subsequently be identified as a case and because, to avoid mismatching, the process to identify transmission was
365 highly specific. Despite freedoms allowed, DCT-participants were still advised to minimise contact and national
366 restrictions were in place at the time of our study, which may have reduced likelihood of onward transmission.
367 There was a skew in the DCT arm towards individuals who were able to work from home, which again would
368 limit opportunities for non-household transmission. Differences in the number of contacts within workplaces and
369 non-household settings could not be fully explored by this work due to national COVID-19 restrictions in place
370 during the study period. Findings may not be generalisable to children, however, other work has investigated DCT
371 in schools (20).

372
373 The study was undertaken as part of real-life management of contacts of COVID-19 cases, providing evidence of
374 the impact that a DCT policy would have, if introduced. Nearly two years since the identification of SARS-CoV-
375 2, the pandemic continues to have a significant impact on individuals and society. Developing public health
376 interventions that mitigate both viral transmission and the wider impacts on health, wellbeing, prosperity, and
377 society, including those arising from self-isolation, is essential. This study shows the potential benefits of daily
378 testing while minimising the need for self-isolation.

379 **Acknowledgement**

381 Logistical and operational support from Laura Morris (DHSC); Dominic Palframan (DHSC); Adam Eccles
382 (DHSC); Alan Waterhouse (DHSC); Tom Fowler (UKHSA); Simon Cockburn; Taran Huxtable; Richard Staker
383 and the Agile lighthouse team (UKHSA); Louise Glendinning and Lisa Callan (UKHSA); Max Helyer (DHSC)
384 and NHSTT call handlers; Ashley Kittle and NHS119 call handlers; Anne-Marie O'Connell; Koren Jones; Ellie
385 Gilham; Mona Dave; Edward Harding; Aryan Nikhab, Meaghan Kall for data support. Cong Chen for vaccination
386 linkage. Charlotte Anderson for contract tracing advice. Sheila Bird for critical review.

387 **Funding**

389 LY is an NIHR Senior Investigator and her research programme is partly supported by NIHR Applied Research
390 Collaboration (ARC)-West, NIHR Health Protection Research Unit (HPRU) for Behavioural Science and
391 Evaluation, and the NIHR Southampton Biomedical Research Centre (BRC).

392 CEF, IO, RA, SD are funded by the NIHR Health Protection Research Unit (HPRU) in Behavioural Science and
393 Evaluation at the University of Bristol.
394 GJR and RA are funded by the NIHR Health Protection Research Unit (HPRU) in Emergency Preparedness and
395 Response at King's College London.
396 AFM is supported by the Economic and Social Research Council Grant Number ES/J500057/1.
397
398


399 References

- 400 1. Department for Health and Social Care. NHS Test and Trace: how it works. Available at:
401 <https://www.gov.uk/guidance/nhs-test-and-trace-how-it-works>
402
- 403 2. UK Health Security Agency. Guidance for contacts of people with confirmed coronavirus (COVID-19)
404 infection who do not live with the person. [https://www.gov.uk/government/publications/guidance-for-](https://www.gov.uk/government/publications/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person)
405 [contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-](https://www.gov.uk/government/publications/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person)
406 [the-person/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-](https://www.gov.uk/government/publications/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person)
407 [infection-who-do-not-live-with-the-person](https://www.gov.uk/government/publications/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person/guidance-for-contacts-of-people-with-possible-or-confirmed-coronavirus-covid-19-infection-who-do-not-live-with-the-person)
408
- 409 3. Denford S, Morton KS, Lambert H, et al. Understanding patterns of adherence to COVID-19
410 mitigation measures: a qualitative interview study. *J Public Health (Oxf)* 2021 Feb 9 : fdab005.
411 Published online 2021 Feb 9. doi: 10.1093/pubmed/fdab005
412
- 413 4. Smith LE, Amlôt R, Lambert H et al. Factors associated with adherence to self-isolation and lockdown
414 measures in the UK: a cross-sectional survey. *J Public Health*. 2020 Oct; 187: 41–52.
415 doi: 10.1016/j.jpuhe.2020.07.024
416
- 417 5. Office for national Statistics. Coronavirus and self-isolation after being in contact with a positive case
418 in England: 9 to 16 August 2021. Available at:
419 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bu](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronavirusandselfisolationafterbeingincontactwithapositivecaseinengland/9to16august2021)
420 [lletins/coronavirusandselfisolationafterbeingincontactwithapositivecaseinengland/9to16august2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronavirusandselfisolationafterbeingincontactwithapositivecaseinengland/9to16august2021)
421
- 422 6. Smith LE, Potts HWW, Amlôt R, Fear NT, Michie S, Rubin GJ. Adherence to the test, trace and
423 isolate system: results from a time series of 21 nationally representative surveys in the UK (the
424 COVID-19 Rapid Survey of Adherence to Interventions and Responses [CORSAIR] study). 2020.
425 Available at: S0732_CORSAIR_-_Adherence_to_the_test__trace_and_isolate_system.pdf
426 (publishing.service.gov.uk)
427
- 428 7. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it:
429 rapid review of the evidence. *Lancet* 2020; 395: 912–20.
430
- 431 8. Quilty BJ, Clifford S, Hellewell J, Russell TW, Kucharski AJ, Flasche S, Quarantine and testing
432 strategies in contact tracing for SARS-CoV-2: a modelling study. *Lancet Public Health* 2021. Available
433 at: [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(20\)30308-X/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30308-X/fulltext)
434
- 435 9. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for
436 Containment. *N Engl J Med*. 2020 Nov 26;383(22):e120
437
- 438 10. Mina MJ, Andersen KG. COVID-19 testing: One size does not fit all. *Science*. 2021 Jan
439 8;371(6525):126-127. doi: 10.1126/science.abe9187. Epub 2020 Dec 21.
440
- 441 11. Department for Health and Social Care. Find out which coronavirus (COVID-19) test you should get.
442 Available at: <https://www.gov.uk/getting-tested-for-coronavirus>
443

- 444 12. UK COVID-19 Lateral Flow Oversight Team. COVID-19: Rapid antigenic detection for SARS-CoV-2
445 by lateral flow assay: a national systematic evaluation for mass-testing. 2020. Available at:
446 <http://modmedmicro.nsms.ox.ac.uk/wp-content/uploads/2021/01/Lateral-Flow.pdf>.
447
- 448 13. Marchant E, Ready D, Wimbury G, Smithson R, Charlett A, Oliver I. 2021 Determining the
449 acceptability of testing contacts of confirmed COVID-19 cases to improve secondary case
450 ascertainment J Public Health (Oxf). DOI: 10.1093/pubmed/fdab079
451
- 452 14. Love, N; Ready D, Turner T, Yardley L, Rubin G. J, Hopkins J, Oliver I. The acceptability of testing
453 contacts of confirmed COVID-19 cases using serial, self-administered lateral flow devices as an
454 alternative to self-isolation - <https://www.medrxiv.org/content/10.1101/2021.03.23.21254168v1>
455
- 456 15. Denford S, Martin AF, Love N, Ready D, Oliver I, Amlôt R, Yardley L, Rubin GJ. Engagement with
457 daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV-2: a qualitative
458 analysis Frontiers in Public Health 2021.
459
- 460 16. Martin AF, Denford S, Love N, Ready D, Oliver I, Amlôt R, Rubin GJ, Yardley L. Engagement with
461 daily testing instead of quarantine following possible exposure to SARS-CoV-2. BMC Public Health
462 2021; 21: 1067. DoI: 0.1186/s12889-021-11135-7
463
- 464 17. Quilty BJ, Clifford S, Hellewell J et al. Quarantine and testing strategies in contact tracing for SARS-
465 CoV-2: a modelling study. Lancet Public Health. 2021 6(3):e175-e183. DoI: 10.1016/S2468-
466 2667(20)30308-X.
467
- 468 18. Young BC, Eyre DW, Kendrick S et al. Daily testing for contacts of individuals with SARS-CoV-2
469 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an
470 open-label, cluster-randomised trial. Lancet 2021; 398(10307):1217-1229. DoI: 10.1016/S0140-
471 6736(21)01908-5
472
- 473 19. Denford S, Martin A.F, Towler L. et al. A qualitative process analysis of DCT as an alternative to self-
474 isolation following close contact with a confirmed case of COVID-19. Pre-print
475
- 476 20. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029536/test-and-trace-oct-14-to-20.pdf)
477 [536/test-and-trace-oct-14-to-20.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029536/test-and-trace-oct-14-to-20.pdf)

478 **Figure 1 – Flow chart of study participation**

479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514



* incomplete records were excluded following recruitment as no address or contact information was provided
 ** If multiple contacts were reported from a single household (concatination of door number and postcode), then all individuals in the household were assigned to the same arm of the study after recruitment, with all individuals assigned to the arm assigned to the first member of the household recruited.
 *** If multiple contacts were reported from a single household (concatination of door number and postcode), then all individuals in the household were assigned to the same arm of the study after recruitment, with all individuals assigned to the arm assigned to the first member of the household recruited.
 **** 5,328 were excluded from the LFD arm as they had not submitted results to the LFD portal and it was not possible to verify that they had participated in the study. Specific exclusion from supplementary attack rate analysis, LFD and PCR concordance.

515 **Table 1 – Socio-demographic characteristics of study participants by study arm**

516

		DCT arm (n=26,123)			PCR arm (n=23,500)			p- value
		Percentage [95% CI] (Number)			Percentage [95% CI] (Number)			
Sex	Female	53.6%	[53 - 54.2%]	(14,000)	54.2%	[53.6 - 54.8%]	(12,734)	0.18
	Male	46.4%	[45.8 - 47%]	(12,113)	45.8%	[45.2 - 46.4%]	(10,756)	
Age	Mean	41.8 years			42 years			0.38
	95% CI	[41.7 – 42.0]			[41.8 - 42.2]			
	Range	18 – 87			18 – 89			
Geography	East Midlands	7.0%	[6.7 - 7.3%]	(1,822)	7.0%	[6.6 - 7.3%]	(1,635)	0.26
	East of England	8.3%	[7.9 - 8.6%]	(2,158)	8.9%	[8.5 - 9.2%]	(2,086)	
	London	11.3%	[10.9 - 11.7%]	(2,947)	11.2%	[10.8 - 11.6%]	(2,627)	
	North East	8.7%	[8.4 - 9.1%]	(2,282)	8.5%	[8.1 - 8.8%]	(1,992)	
	North West	18.8%	[18.4 - 19.3%]	(4,917)	19.3%	[18.8 - 19.8%]	(4,524)	
	South East	14.6%	[14.2 - 15%]	(3,813)	14.2%	[13.7 - 14.6%]	(3,331)	
	South West	10.7%	[10.3 - 11%]	(2,782)	10.4%	[10 - 10.8%]	(2,446)	
	West Midlands	8.4%	[8.1 - 8.8%]	(2,199)	8.5%	[8.1 - 8.8%]	(1,995)	
	Yorkshire & Humber	12.2%	[11.8 - 12.6%]	(3,176)	12.2%	[11.7 - 12.6%]	(2,856)	
Index of multiple deprivation	1 - Most deprived	5.8%	[5.5 - 6%]	(1,493)	6.0%	[5.7 - 6.3%]	(1,403)	0.04
	2	6.3%	[6 - 6.6%]	(1,630)	6.8%	[6.5 - 7.1%]	(1,589)	
	3	7.4%	[7 - 7.7%]	(1,912)	7.7%	[7.3 - 8%]	(1,788)	
	4	8.4%	[8.1 - 8.8%]	(2,194)	8.4%	[8.1 - 8.8%]	(1,972)	
	5	9.7%	[9.3 - 10.1%]	(2,521)	9.3%	[8.9 - 9.7%]	(2,168)	
	6	10.3%	[9.9 - 10.7%]	(2,672)	10.4%	[10 - 10.7%]	(2,418)	
	7	11.7%	[11.3 - 12.1%]	(3,032)	11.8%	[11.3 - 12.2%]	(2,745)	
	8	12.3%	[11.8 - 12.6%]	(3,182)	12.5%	[12.1 - 12.9%]	(2,922)	
	9	12.9%	[12.5 - 13.3%]	(3,357)	12.6%	[12.2 - 13.1%]	(2,952)	
	10 - Least deprived	15.4%	[14.9 - 15.8%]	(3,993)	14.6%	[14.1 - 15%]	(3,399)	
Ethnicity	Asian	3.3%	[3.1 - 3.5%]	(856)	3.6%	[3.3 - 3.8%]	(826)	0.12
	Black	1.0%	[0.9 - 1.1%]	(264)	1.0%	[0.9 - 1.2%]	(241)	
	Mixed	2.7%	[2.5 - 2.9%]	(707)	2.5%	[2.3 - 2.6%]	(569)	
	White	91.8%	[91.4 - 92.1%]	(304)	91.9%	[91.4 - 92.1%]	(250)	

	Other	1.2%	[1 - 1.3%]	(23,718)	1.1%	[91.5 - 92.2%]	(21,346)	
Self-reported vaccination*	Unvaccinated	13.1%	[12.7 - 13.5%]	(3,390)	13.0%	[12.5 - 13.4%]	(3,022)	0.02
	1 dose	24.6%	[24 - 25.1%]	(6,343)	25.7%	[25.1 - 26.2%]	(5,978)	
	2 doses	62.3%	[61.7 - 62.9%]	(16,103)	61.4%	[60.7 - 62%]	(14,291)	
Case in household**	No	39.3%	[38.7 – 39.9%]	(10,134)	40.3%	[39.7 – 41%]	(9,376)	0.02
	Yes	60.7%	[60.1 – 61.3%]	(15,666)	59.7%	[59 – 60.3%]	(13,877)	
Homeworker***	No	40.1%	[39.5 - 40.7%]	(10,324)	43.2%	[42.6 - 43.9%]	(10,035)	<0.001
	Yes	59.9%	[59.3 - 60.5%]	(15,424)	56.8%	[56.1 - 57.4%]	(13,175)	
Household multiple****	No	58.3%	[57.7 - 58.9%]	(15,239)	63.9%	[63.2 - 64.5%]	(15,006)	<0.001
	Yes	41.7%	[41.1 - 42.3%]	(10,884)	36.1%	[35.5 - 36.8%]	(8,494)	

517

518 * Self-reported vaccination status. Question: ‘Have you received a vaccination for COVID-19’. Options; Yes – 2
519 doses, Yes – 1 dose, No.

520 ** Self-reported. Question: ‘Does the person with COVID-19 that you were exposed to live in your household?’.
521 Options; Yes, No.

522 *** Self-reported. Question: ‘Are you able to work from home?’. Single choice options; Yes, No.

523 **** Derived from house number and postcode given at recruitment. Participants with same postcode and house
524 number grouped as household members. Includes individuals registered more than once if more than 3 days from
525 first registration.

526 ¹ Data completeness for sex n=23,490 PCR (100%) and 26,113 DCT (100%). Pearson Chi²=1.77

527 Data completeness for age n=23,153 PCR (98.5%) and 25,749 DCT (98.6%). Mann-Whitney

528 Data completeness for geography (PHE region) n=23,492 PCR (100 %) and 26,096 DCT (99.9%). Pearson Chi²
529 =10.04

530 Data completeness for index of multiple deprivation (IMD) n=23,356 in PCR (99.4%) and 25,986 DCT (99.5%).
531 Pearson Chi²=10.04

532 Data completeness for ethnicity n=23,232 PCR (98.9%) and 25,849 DCT (99.0%). Pearson Chi²=8.69

533 Data completeness for self-reported vaccination status n=23,291 PCR (99.1%) and 25,836 DCT (98.9%). Pearson
534 Chi²=8.14

535 Data completeness for index case being in household n=23,253 PCR (98.9%) and 25,800 DCT (98.8%). Pearson
536 Chi²=5.55

537 Data completeness for self-reported ability to work from home n=23,210 in PCR (98.8%) and 25,748 DCT
538 (98.6%). Pearson Chi²=49.52

539 Data completeness for having more than one household member/an individual being registered more than once in
540 the study n=23,500 PCR (100%) and 26,123 DCT (100%). Pearson Chi²=158.36

541 **Table 2 – Number of COVID-19 PCR positive participants (secondary cases), their contacts (secondary**
 542 **contacts) and the number of tertiary cases identified in CTAS records**

543

	DCT	SI	Total
Number of PCR positive cases among study participants (secondary cases)	2,202	2,359	4,561
Number of PCR positive cases among study participants (secondary cases) identified in CTAS	2,230	2,385	4,615
Number of secondary cases with CTAS secondary contacts	1,762	1,948	3,710
Number of secondary cases with CTAS household secondary contacts	1,727	1,922	3,649
Number of secondary cases with CTAS non-household secondary contacts	219	214	433
Number of secondary contacts	4,909	5,206	10,115
Number of household secondary contacts	4,305	4,638	8,943
Number of non-household secondary contacts	604	568	1,172
Number of tertiary cases	314	390	704
Number of tertiary cases from household contacts	296	370	666
Number of tertiary cases from non-household contacts	18	20	38
Number of secondary contacts per participant case (all cases)	2.2	2.2	2.2
Number of secondary contacts per participant case (cases with contacts)	2.8	2.7	2.7
Number of household secondary contacts per participant case (all cases)	1.9	1.9	1.9
Number of household secondary contacts per participant case (cases with household contacts)	2.5	2.4	2.5
Number of non-household secondary contacts per participant case (all cases)	0.3	0.2	0.3
Number of non-household secondary contacts per participant case (cases with non-household secondary contacts)	2.8	2.7	2.7
Number of tertiary cases per CTAS secondary case	0.1	0.2	0.2
Number of tertiary cases per secondary case via household secondary contact	0.1	0.2	0.1
Number of tertiary cases per secondary case via non-household secondary contact	0.01	0.01	0.01

544

545 * where a case had multiple records, all were included

546

547

548

549

550

551

552 **Table 3 – Attack rates in secondary contacts and difference in percentages amongst secondary contacts**

553

Attack rates in secondary contacts		Percent positive	95% Confidence interval	Percent positive	95% Confidence interval
		Unadjusted (n = 10,115)		Adjusted (n = 9,962)	
DCT arm		6.40%	(5.67%, 7.13%)	6.40%	(5.67%, 7.12%)
SI arm		7.49%	(6.71%, 8.27%)	7.44%	(6.67%, 8.22%)
Difference in percentage	DCT vs SI arms	-1.09%	(-2.16%, -0.03%)	-1.04%	(-2.11%, 0.02%)
		Unadjusted (n = 10,115)		Adjusted (n = 9,962)	
DCT arm: household secondary contacts		6.88%	(6.08%, 7.67%)	6.88%	(6.07%, 7.68%)
SI arm: household secondary contacts		7.98%	(7.13%, 8.82%)	7.96%	(7.11%, 8.81%)
DCT arm: non-household secondary contacts		2.98%	(1.52%, 4.44%)	2.79%	(1.37%, 4.21%)
SI arm: non-household secondary contacts		3.52%	(1.90%, 5.14%)	3.55%	(1.92%, 5.18%)
Difference in percentage	DCT vs SI: household secondary contacts	-1.10%	(-2.26%, 0.06%)	-1.08%	(-2.25%, 0.09%)
	DCT vs SI: non-household secondary contacts	-0.54%	(-2.72%, 1.64%)	-0.77%	(-2.95%, 1.41%)
		Unadjusted (n = 10,077)		Adjusted (n = 9,962)	
DCT arm: 0 or 1 dose vaccine		6.93%	(5.88%, 7.98%)	7.07%	(6.03%, 8.11%)
SI arm: 0 or 1 dose vaccine		7.78%	(6.72%, 8.85%)	7.81%	(6.75%, 8.88%)
DCT arm: 2 doses vaccine		5.72%	(4.71%, 6.73%)	5.62%	(4.63%, 6.62%)
SI arm: 2 doses vaccine		7.06%	(5.94%, 8.17%)	7.01%	(5.90%, 8.13%)
Difference in percentage	DCT vs SI: 0 or 1 dose vaccine	-0.85%	(-2.34%, 0.64%)	-0.74%	(-2.23%, 0.74%)
	DCT vs SI: 2 doses vaccine	-1.33%	(-2.84%, 0.17%)	-1.40%	(-2.91%, 0.11%)

554

555 ‘Unadjusted’ models include named variables (arm, arm and household exposure, and arm and vaccination status)
 556 as covariates. ‘Adjusted’ versions of these models were obtained by adding all others from household exposure,
 557 vaccine status and ability to work from home. SI was used as a baseline against which DCT was compared. Model
 558 testing for significance of arm and household exposure interaction and arm and vaccination status interaction were
 559 not significant (Unadjusted model arm and household exposure: p=0.97, adjusted model arm and household
 560 exposure: p=0.81 and unadjusted model arm and vaccination status: p=0.56, adjusted model arm and vaccination
 561 status: p=0.46 respectively).

562

563

564 **Table 4 - PCR results by test and by participant**

565

	PCR arm	DCT arm	Total
	Results by test		
Result			
Negative	23,388	33,090	56,478
Positive	2,790	2,203	4,993
Void	316	403	719
Total	26,494	35,696	62,190
	Results by participant		
Result			
Negative and/or void only	14,985	15,967	30,952
Positive	2,359	1,647	4,006
Total	17,344	17,614	34,958
Proportion positive	13.6%	9.4%	11.5%

566

Responses		PCR (N=8,807)		DCT – tested positive (N=754)		DCT - no positive test (N=10,443)		p- value [^]
		n	%**	n	%**	n	%**	
1. Last 24-hour activities *	Work, college, university	72	25%	24	20%	2,462	29%	0.028
	Other indoor place	105	37%	42	35%	3,813	45%	0.001
	Outdoors with friends/family	72	25%	21	17%	2,349	28%	0.023
	Indoors with friends/family	54	19%	9	7%	1,146	14%	0.005
	Any other reason	110	39%	67	55%	2,984	35%	<0.001
	None of these*	487	63%	631	84%	2,029	20%	<0.001
2. 7 days close contacts during study period	Much more	209	2%	9	1%	374	4%	<0.001
	Slightly more	289	3%	20	3%	742	7%	
	About the same	699	8%	67	9%	1,801	17%	
	Slightly less	415	5%	28	4%	1,563	15%	
	Much less	7,180	82%	626	84%	5,946	57%	
3. Confidence in test accuracy	Completely	3,590	43%	255	40%	4,638	44%	<0.001
	Very	2,997	36%	156	24%	4,025	39%	
	Fairly	1,510	18%	121	19%	1,617	16%	
	Not very	180	2%	68	11%	127	1%	
	Not at all	69	1%	44	7%	33	0%	
4. Activities whilst self-isolating	Work, college, university	713	19%	29	13%	-	-	0.055
	Other indoor place	1,264	33%	107	48%	-	-	<0.001
	Outdoors with friends/family	918	24%	49	22%	-	-	0.638
	Indoors with friends/family	684	18%	29	13%	-	-	0.096
	Left home for any other reason	3,122	81%	168	76%	-	-	0.088
5. Reasons for leaving home when isolating[†]	Earn money	74	2%	4	2%	-	-	0.992
	Keep my job	59	1%	4	2%	-	-	0.609
	Practical reasons (shopping, caring etc)	393	8%	13	6%	-	-	0.328
	Mental health	668	14%	15	7%	-	-	0.005
	Other important things	265	6%	18	9%	-	-	0.100

Probably not infectious	152	3%	8	4%	-	-	0.787
I didn't leave home+	4,099	47%	532	73%	-	-	<0.001
To take a coronavirus test	4,084	87%	182	87%	-	-	1.000

569

570 Items are as follows:

- 571 1. Thinking about yesterday, please tick all the things you did (Data completeness: 8.7% (769/8,807) in
572 PCR arm, 99.7% (752 /754) in DCT – tested positive group , 99.9% (10,431/10,443) in DCT –no positive
573 test group provided at least one response to items 1 -6)
574 2. Compared to the week before, in the last 7 days did you have more or less close contact with people you
575 don't live with, indoors and for more than 15 minutes? (Data completeness: 99.8% (8,792/8,807) in PCR
576 arm, 99.5% (750/754) in DCT –tested positive group , 99.8% (10,426/10,443) in DCT –no positive test
577 group responded to this question)
578 3. [If yes to: In the past 7 days, did you take any tests for coronavirus] How confident are you that your test
579 results were accurate? (Data completeness: 94.8% (8,346/8,807) in PCR arm, 85.4% (644/754) in DCT
580 – tested positive group , 100.0% (10,440/10,443) in DCT –no positive test group responded to this
581 question)
582 4. Thinking about the last 7 days, how often have you done each of these things [since getting your first
583 positive test result] (note: these were recoded as binary never vs once or more, options were: never, once
584 or twice, three or four times, five times or more) (Data completeness: 43.8% (3,858/8.807) in PCR arm,
585 29.3% (221/754) in DCT - tested positive group provided at least one response to items 1 -5)
586 5. Did you leave home [following a positive test result / during your self-isolation period] for any of the
587 following reasons? (Please tick all that apply) (Data completeness: 98.5% (8,678/8.807) in PCR arm,
588 97.2% (733/754) in DCT - tested positive group provided at least one response to items 1 -8)

589 * Percentages for responses 1-5 are calculated from those who reported leaving home; for response 6 (none of
590 these) the proportion is calculated among those who responded to any of items 1-6.

591 ** Except where noted, percentages are calculated from those who responded to each question

592 + Percentages for responses 1-6 are calculated from those who reported at least one reason for leaving home, this
593 includes people who left home to take a coronavirus test [data not presented here]; for response 7 (I didn't leave
594 home) the proportion is calculated among those who provided at least one response to this question.

595 ^ For items where respondents were asked to tick all responses that applied to them, p-values were calculated for
596 each 2x2 comparison. For items where respondents were asked to select a single response, an overall p-value was
597 calculated for that item.